Exit
Portfolio company Engage Bio acquired by Eli Lilly for up to $202M for non-viral DNA delivery platform.
Engage Bio
Every public signal F4 has attached to this firm, with sources and cross-entity links.
Engage Bio
Krave Mart
Giant
NORDA Dynamics
Unpopular Ventures: Annual Update 2025